ReviewWorld journal of surgical oncology2025
The multifaceted roles of ribosomal P complex in cancer.
Review in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Article
- RPLP0 identified as a ferroptosis regulator in HCC through pan-cancer analysis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The ribosomal P complex, a flexible lateral stalk structure of the ribosomal large subunit, consists of the RPLP0, RPLP1, and RPLP2 proteins, and is essential for the elongation phase of protein biosynthesis. Notably, RPLP proteins have been implicated in various pathological conditions, including autoimmune disorders, degenerative diseases, while recent studies have elucidated their biological functions and underlying mechanisms in cancer. This review summarizes the structural and functional aspects of ribosomal stalk proteins, their expression levels across different cancers, and their impact on cancer progression. Additionally, we describe the molecular networks involving these proteins and how their regulatory mechanisms contribute to the hallmark characteristics of cancer phenotypes. Targeting RPLP proteins represents a novel strategy for achieving better treatment outcome of cancer patients in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.